| Date Filed | Type | Description |
| 10/02/2023 |
8-K
| Quarterly results |
| 08/22/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 08/09/2023 |
4
| Musso Alan A (CFO) has filed a Form 4 on Fulcrum Therapeutics, Inc.|
Txns:
| Granted 432,800 options to buy
@ $4.01, valued at
$1.7M
|
|
| 08/09/2023 |
3
| Musso Alan A (CFO) has filed a Form 3 on Fulcrum Therapeutics, Inc. |
| 08/03/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
8-K
| Quarterly results |
| 07/10/2023 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 07/07/2023 |
SC 13G/A
| BlackRock Inc. reports a 2.5% stake in FULCRUM THERAPEUTICS INC |
| 07/03/2023 |
3
| Sapir Alex (See Remarks) has filed a Form 3 on Fulcrum Therapeutics, Inc. |
| 06/29/2023 |
4
| GERAGHTY JAMES A (Director) has filed a Form 4 on Fulcrum Therapeutics, Inc.|
Txns:
| Granted 30,000 options to buy
@ $3.16, valued at
$94.8k
|
|
| 06/29/2023 |
4
| Haviland Kate (Director) has filed a Form 4 on Fulcrum Therapeutics, Inc.|
Txns:
| Granted 30,000 options to buy
@ $3.16, valued at
$94.8k
|
|
| 06/29/2023 |
4
| Dorton Katina (Director) has filed a Form 4 on Fulcrum Therapeutics, Inc.|
Txns:
| Granted 30,000 options to buy
@ $3.16, valued at
$94.8k
|
|
| 06/29/2023 |
4
| Banks Sonja (Director) has filed a Form 4 on Fulcrum Therapeutics, Inc.|
Txns:
| Granted 30,000 options to buy
@ $3.16, valued at
$94.8k
|
|
| 06/29/2023 |
4
| Ezekowitz Alan (Director) has filed a Form 4 on Fulcrum Therapeutics, Inc.|
Txns:
| Granted 30,000 options to buy
@ $3.16, valued at
$94.8k
|
|
| 06/29/2023 |
4
| Gould Robert J (Interim President & CEO) has filed a Form 4 on Fulcrum Therapeutics, Inc.|
Txns:
| Granted 30,000 options to buy
@ $3.16, valued at
$94.8k
|
|
| 06/29/2023 |
4
| Collins James J. (Director) has filed a Form 4 on Fulcrum Therapeutics, Inc.|
Txns:
| Granted 30,000 options to buy
@ $3.16, valued at
$94.8k
|
|
| 06/09/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/15/2023 |
8-K
| Quarterly results |
| 05/11/2023 |
4
| Tourangeau Greg (Principal Accounting Officer) has filed a Form 4 on Fulcrum Therapeutics, Inc.|
Txns:
| Sold 210 shares
@ $3.31, valued at
$695.1 |
|
| 04/28/2023 |
4
| Hayes Melvin H. III (COO) has filed a Form 4 on Fulcrum Therapeutics, Inc.|
Txns:
| Granted 115,000 options to buy
@ $2.58, valued at
$296.7k
|
|
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/18/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/05/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/09/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/09/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/09/2023 |
8-K
| Quarterly results |
| 03/06/2023 |
SC 13G
| ADAGE CAPITAL PARTNERS GP, L.L.C. reports a 5.6% stake in Fulcrum Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Third Rock Ventures III, L.P. reports a 4.5% stake in Fulcrum Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|